Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prucalopride - Takeda

Drug Profile

Prucalopride - Takeda

Alternative Names: Motegrity; R 093877; R 108512; R 93877; Resolor; Resotran; Resotrans; Rezolor; SHP555; SPD-555

Latest Information Update: 09 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen
  • Developer Janssen; Shire-Movetis NV; Takeda; University of Calgary
  • Class Amides; Benzofurans; Gastrokinetics; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation
  • Phase II/III Diabetic gastroparesis
  • No development reported Postoperative ileus

Most Recent Events

  • 09 Apr 2019 Planned Prescription Drug User Fee Act (PDUFA) date for Constipation in USA (PO) is 2018-12-21
  • 02 Apr 2019 Launched for Constipation in USA (PO)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top